Literature DB >> 29904925

Use of fluorescein isothiocyanate isomer I to study the mechanism of intestinal absorption of fucoidan sulfate in vivo and in vitro.

E Zhang1,2, Fulong Chu1,2,3, Lixu Xu1,2, Hao Liang1,2, Shuliang Song1,2, Aiguo Ji1,2,4.   

Abstract

A new method to label fucoidan sulfate was established with tyramine and fluorescein isothiocyanate isomer I (FITC). Fluorescence spectrophotometry and high performance liquid chromatography verified the successful labelling of fucoidan by FITC. The results of the single-pass intestinal perfusion indicated that the jejunum and ileum are the main absorption sites, and there was carrier saturation. In addition, fucoidan sulfate at 1 mg/ml had no inhibitory effect on Caco-2 cell proliferation. Studies on the transmembrane transport mechanism showed that fucoidan can be absorbed because the apparent permeability coefficient of the drugs (Papp ) A → B was 3.78 + 0.03 ×10-6 and that of B → A was 1.42 + 0.19 ×10-6 . The peak absorption of fucoidan occurred at 120 min after administration; moreover, the higher the concentration used, the worse the absorption was, suggesting the saturation of transport carriers. The absorption was temperature dependent: the absorption at 37°C was much better than that at 4°C. Further, the absorption of fucoidan sulfate might rely on clathrin endocytosis as chlorpromazine (10 μg/ml) significantly inhibited it.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Caco-2 cells; FITC labelling; clathrin; fucoidan; single-pass intestinal perfusion

Mesh:

Substances:

Year:  2018        PMID: 29904925     DOI: 10.1002/bdd.2137

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  7 in total

1.  Orally Administered Halofuginone-Loaded TPGS Polymeric Micelles Against Triple-Negative Breast Cancer: Enhanced Absorption and Efficacy with Reduced Toxicity and Metastasis.

Authors:  Runan Zuo; Yan Zhang; Xiaorong Chen; Shiheng Hu; Xinhao Song; Xiuge Gao; Jiahao Gong; Hui Ji; Fengzhu Yang; Lin Peng; Kun Fang; Yingjun Lv; Junren Zhang; Shanxiang Jiang; Dawei Guo
Journal:  Int J Nanomedicine       Date:  2022-05-30

2.  Application of Fucoidan in Caco-2 Model Establishment.

Authors:  Qiong Yang; Maochen Xing; Ke Wang; Qiang Wei; Jiarui Zhao; Yuan Wang; Kai Ji; Shuliang Song
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-30

3.  Are Helicobacter pylori Infection and Fucoidan Consumption Associated with Fucoidan Absorption?

Authors:  Makoto Tomori; Takeaki Nagamine; Masahiko Iha
Journal:  Mar Drugs       Date:  2020-04-30       Impact factor: 5.118

Review 4.  Therapies from Fucoidan: New Developments.

Authors:  Helen J Fitton; Damien S Stringer; Ah Young Park; Samuel N Karpiniec
Journal:  Mar Drugs       Date:  2019-10-09       Impact factor: 5.118

5.  Study on Absorption Mechanism and Tissue Distribution of Fucoidan.

Authors:  Xu Bai; E Zhang; Bo Hu; Hao Liang; Shuliang Song; Aiguo Ji
Journal:  Molecules       Date:  2020-02-28       Impact factor: 4.411

6.  High Molecular Weight Fucoidan Restores Intestinal Integrity by Regulating Inflammation and Tight Junction Loss Induced by Methylglyoxal-Derived Hydroimidazolone-1.

Authors:  Jae-Min Lim; Hee Joon Yoo; Kwang-Won Lee
Journal:  Mar Drugs       Date:  2022-09-17       Impact factor: 6.085

7.  Stimulating the Hematopoietic Effect of Simulated Digestive Product of Fucoidan from Sargassum fusiforme on Cyclophosphamide-Induced Hematopoietic Damage in Mice and Its Protective Mechanisms Based on Serum Lipidomics.

Authors:  Wei-Ping Ma; Shi-Ning Yin; Jia-Peng Chen; Xi-Cheng Geng; Ming-Fei Liu; Hai-Hua Li; Ming Liu; Hong-Bing Liu
Journal:  Mar Drugs       Date:  2022-03-09       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.